Frontiers in Genetics (Aug 2022)

A multi-omic approach reveals utility of CD45 expression in prognosis and novel target discovery

  • Ni Ye,
  • Jie Cai,
  • Yulong Dong,
  • Huiyao Chen,
  • Zhiyuan Bo,
  • Xiaogang Zhao,
  • Mingyang Xia,
  • Mei Han

DOI
https://doi.org/10.3389/fgene.2022.928328
Journal volume & issue
Vol. 13

Abstract

Read online

CD45, the leukocyte common antigen, is expressed on almost all cells of the immunological and hematological systems. CD45 expression is related to a variety of diseases, including leukemia and lymphoma. In this study, we analyzed the expression level of CD45 across cancers and evaluated the relationship between its expression and patient prognosis. We further integrated methylation data to explore the differences in CD45 across cancers from a multi-omics perspective. We also analyzed the relationship between CD45 expression and levels of immune cell infiltrates and immune modifiers. Our results revealed the distinct expression characteristics and prognostic value of CD45 across multiple tumors. In addition, we screened drug targets based on the immune index defined by CD45 expression and identified that GPR84 affected the proliferation of tumor cells and was associated with the inflammation caused by immunotherapy. In summary, our findings provide a comprehensive understanding of the role of CD45 in oncogenesis and its prognostic significance across cancers.

Keywords